Literature DB >> 2457005

Radiotherapy for chordoma.

D B Fuller1, J G Bloom.   

Abstract

Twenty-five patients with gross residual chordoma after partial excision or biopsy were treated by radical radiotherapy at Royal Marsden Hospital between 1952 and 1981. The median duration of freedom from local progression following radiotherapy was 32 months. Twenty-four of the 25 patients (96%) had stabilization or reduction in symptoms. All 19 patients in whom pain was a major symptom had relief. The overall actuarial 5- and 10-year survival rates were 44% and 17%, respectively. The corresponding progression--free survival rates were 33% and 20%. Permanent cure was unusual with any radiotherapy dose, but doses higher than 55 Gy or a TDF of 90 were associated with a statistically significant improvement in duration of local control. Seven of 17 (41%) patients who received greater than 55 Gy had freedom from local progression for 5 or more years compared with only 1 of 8 patients receiving less than 50 Gy. Subtotal excision prior to radiotherapy did not appear to improve median survival or probability of long-term local control. Distant metastases were seen in 16% of the patients, derived entirely from sacrococcygeal lesions, but only half of these caused significant morbidity or death. Local control is obviously the overwhelming problem. High dose, generous volume radiotherapy is advocated.

Entities:  

Mesh:

Year:  1988        PMID: 2457005     DOI: 10.1016/s0360-3016(98)90012-8

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  19 in total

Review 1.  Multidisciplinary management of primary tumors of the vertebral column.

Authors:  Wesley Hsu; Thomas A Kosztowski; Hasan A Zaidi; Michael Dorsi; Ziya L Gokaslan; Jean-Paul Wolinsky
Journal:  Curr Treat Options Oncol       Date:  2009-06-23

2.  Clivus chordoma: a report of 12 recent cases and review of the literature.

Authors:  J W Harbour; M T Lawton; G R Criscuolo; M J Holliday; D E Mattox; D M Long
Journal:  Skull Base Surg       Date:  1991

3.  Combination of PARP inhibitor and temozolomide to suppress chordoma progression.

Authors:  Xiaoyu Cao; Yanxin Lu; Yang Liu; Yiqiang Zhou; Hua Song; Wei Zhang; Dionne Davis; Jing Cui; Shuyu Hao; Jinkyu Jung; Qixin Wu; Deric M Park; Chunzhang Yang
Journal:  J Mol Med (Berl)       Date:  2019-06-14       Impact factor: 4.599

Review 4.  Infantile clivus chordoma without clivus involvement: case report and review of the literature.

Authors:  D Kombogiorgas; E J St George; S Chapman; M English; G A Solanki
Journal:  Childs Nerv Syst       Date:  2006-03-25       Impact factor: 1.475

5.  Feasibility of proton beam therapy for chordoma and chondrosarcoma of the skull base.

Authors:  Hiroshi Fuji; Yoko Nakasu; Yuji Ishida; Satoshi Horiguchi; Koichi Mitsuya; Hiroya Kashiwagi; Shigeyuki Murayama
Journal:  Skull Base       Date:  2011-05

6.  [18F]-Fluoromisonidazole positron emission tomography/computed tomography visualization of tumor hypoxia in patients with chordoma of the mobile and sacrococcygeal spine.

Authors:  Matthew D Cheney; Yen-Lin Chen; Ruth Lim; Barbara K Winrich; Anca L Grosu; Alexei V Trofimov; Nicolas Depauw; Helen A Shih; Joseph H Schwab; Francis J Hornicek; Thomas F DeLaney
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-12-01       Impact factor: 7.038

Review 7.  Sacrococcygeal chordoma metastatic to the brain with review of the literature.

Authors:  W A Hall; H B Clark
Journal:  J Neurooncol       Date:  1995       Impact factor: 4.130

Review 8.  Proton therapy in chordoma of the base of the skull: a systematic review.

Authors:  Maurizio Amichetti; Marco Cianchetti; Dante Amelio; Riccardo Maurizi Enrici; Giuseppe Minniti
Journal:  Neurosurg Rev       Date:  2009-03-25       Impact factor: 3.042

Review 9.  Chemotherapy for cranial base tumors.

Authors:  H E Jacob
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

10.  Surgical management of chordoma: A systematic review.

Authors:  Luca Denaro; Alessandra Berton; Mauro Ciuffreda; Mattia Loppini; Vincenzo Candela; Maria Luisa Brandi; Umile Giuseppe Longo
Journal:  J Spinal Cord Med       Date:  2018-07-26       Impact factor: 1.985

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.